Physician profile
Jonathan Cappel
NPI 1174819049
$3,522.75
in general payments reported to CMS, 2019-2025
28 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $209 · 2021: $633 · 2022: $108 · 2023: $789 · 2024: $683 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $475.62 | 2019-2021 | |
| Abbvie INC. | $380.84 | 2023-2025 | Skyrizi, Botox |
| Allergan, INC. | $350.47 | 2021-2022 | |
| Genzyme Corporation | $281.98 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $196.70 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $188.29 | 2019-2023 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $171.50 | 2020-2025 | |
| Janssen Biotech, INC. | $148.21 | 2023-2025 | Tremfya |
| Kerecis Limited | $125.64 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Verrica Pharmaceuticals INC. | $124.98 | 2024 | Ycanth |
| Sun Pharmaceutical Industries INC. | $120.98 | 2023-2025 | Ilumya |
| Journey Medical Corporation | $114.56 | 2021 | |
| Almirall LLC | $104.92 | 2019 | |
| Aclaris Therapeutics, INC. | $98.14 | 2019 | |
| Organogenesis INC. | $97.52 | 2024 | Puraply Wound Matrix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.62 | 2023-2025 | Spevigo |
| Lilly USA, LLC | $81.38 | 2020-2021 | |
| Leo Pharma INC. | $67.62 | 2022-2023 | Adbry |
| Smith+Nephew, INC. | $47.42 | 2024 | Grafix Xc |
| Biofrontera INC. | $39.23 | 2025 | |
| Amgen INC. | $36.77 | 2023-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $36.54 | 2024-2025 | Zoryve |
| Pfizer INC. | $31.09 | 2021 | |
| Mayne Pharma Commercial LLC | $30.70 | 2025 | |
| Genentech USA, INC. | $26.67 | 2019-2020 | |
| Kyowa Kirin, INC. | $20.41 | 2024 | Poteligeo |
| Bioventus LLC | $18.55 | 2023 | |
| Galderma Laboratories, L.P. | $14.40 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cappel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.